Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 6, 2019 - Issue 3
Submit an article Journal homepage
1,728
Views
4
CrossRef citations to date
0
Altmetric
Author's views

Tracking tumor evolution one-cell-at-a-time

Ankur SharmaCancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, SingaporeCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6862-136XView further author information
ORCID Icon &
Ramanuj DasGuptaCancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, SingaporeCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9015-3729View further author information
ORCID Icon
Article: 1590089 | Received 11 Feb 2019, Accepted 01 Mar 2019, Published online: 02 Apr 2019

References

  • Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys Acta (BBA)-Rev Cancer. 2010;1805(1):105–117. doi:10.1016/j.bbcan.2009.11.002.
  • Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–28.
  • McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018.
  • Linnarsson S, Teichmann SA. Single-cell genomics: coming of age. Genome Biol. 2016;97. doi:10.1186/s13059-016-0960-x.
  • Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714. doi:10.1038/nrc3599.
  • Chia S, Low J-L, Zhang X, Kwang X-L, Chong F-T, Sharma A, Bertrand D, Toh SY, Leong H-S, Thangavelu MT, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017;8(1):435. doi:10.1038/s41467-017-00451-5.
  • Sharma A, Cao EY, Kumar V, Zhang X, Leong HS, Wong AML, Ramakrishnan N, Hakimullah M, Teo HMV, Chong FT, et al. Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. Nat Commun. 2018;9(1):4931. doi:10.1038/s41467-018-07261-3.
  • Singh A, Settleman JEMT. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741. doi:10.1038/onc.2010.378.
  • Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511(7508):246. doi:10.1038/nature13305.
  • Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067. doi:10.1038/nature09504.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.